Get the Stockscreener App
15.61
1.69%
0.26
After Hours:
15.61
Neuropace Inc stock is traded at $15.61, with a volume of 126.36K.
It is up +1.69% in the last 24 hours and up +10.79% over the past month.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
See More
Previous Close:
$15.35
Open:
$15.35
24h Volume:
126.36K
Relative Volume:
0.64
Market Cap:
$525.54M
Revenue:
$99.99M
Net Income/Loss:
$-21.47M
P/E Ratio:
-23.66
EPS:
-0.6597
Net Cash Flow:
$-11.34M
1W Performance:
+5.47%
1M Performance:
+10.79%
6M Performance:
+42.17%
1Y Performance:
+50.97%
1-Day Range:
$15.35
$15.67
1-Week Range:
$14.04
$15.67
52-Week Range:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
15.61 | 516.79M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
Day Trade: Is NeuroPace Inc a stock for growth or value investorsMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Here's why you should add NeuroPace stock to your portfolio now - MSN
Understanding Momentum Shifts in (NPCE) - Stock Traders Daily
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference - Investing News Network
Forecast Cut: Will NeuroPace Inc stock benefit from M AMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Aug EndMonth: Should I hold or sell NeuroPace Inc nowWeekly Risk Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Quarterly Recap: Whats the analyst consensus on NeuroPace IncM&A Rumor & Weekly High Return Stock Forecasts - baoquankhu1.vn
NeuroPace (NPCE) up 0.9% since last earnings report: Can it continue? - MSN
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
Neuropace, Inc. (NPCE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Neuropace, Inc. (NPCE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
NeuroPace, Inc. (NPCE) stock price, news, quote and history - Yahoo Finance UK
NeuroPace Earnings Call Highlights Growth And AI Push - The Globe and Mail
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time - Bitget
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Zacks Investment Research
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High? - sharewise.com
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative - Yahoo Finance
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace Inc urges epilepsy patients to evaluate RNS System through online quiz - Traders Union
Avoiding Lag: Real-Time Signals in (NPCE) Movement - Stock Traders Daily
Global Neuromodulation Closed-Loop Brain-Computer Interfaces Market Set for 16.4% CAGR Surge Through 2036, Led by the United States, India & China; Key Players Medtronic, NeuroPace, Synchron Drive Algorithm-Centric Innovation - Morningstar
NeuroPace (NPCE) CMO has 1,341 shares withheld for RSU tax - Stock Titan
Aug Selloffs: What makes NeuroPace Inc stock attractive todayMarket Weekly Review & Weekly High Momentum Picks - baoquankhu1.vn
Director at NeuroPace (NPCE) receives 913-share stock grant and controls large fund stake - Stock Titan
NeuroPace director granted 865 shares at $13 | NPCE Insider Trading - Stock Titan
NeuroPace (NPCE) director gets 1,153-share stock grant as board fees - Stock Titan
NeuroPace (NPCE) director receives 1,826-share equity grant in lieu of cash fees - Stock Titan
NeuroPace, Inc. (NPCE) may report negative earnings: Know the trend ahead of next week's release - MSN
Discipline and Rules-Based Execution in NPCE Response - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Kestra Medical Technologies Ltd. (KMTS), NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company - MarketBeat
Wells Fargo Upgrades NeuroPace(NPCE.US) to Buy Rating, Raises Target Price to $19 - Moomoo
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions - Yahoo Finance
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen - MarketBeat
NPCE SEC FilingsNeuropace Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NeuroPace falls after setback in trial for neuromodulation system - MSN
Published on: 2026-03-12 04:41:05 - baoquankhu1.vn
NeuroPace at Leerink Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
NeuroPace to Present at the Leerink Global Healthcare Conference - aijourn.com
Key Factors Expected to Influence NPCE Stock Performance in 2026 - Bitget
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 - TradingView
NPCE RNS System Explained: Growth Drivers and Setup for 2026 - TradingView
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand - Yahoo Finance
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):